LONZA GROUP AG 12 AUGUST 2025_EN

LATEST COMPANY ANNOUNCEMENT

Lonza Group AG

SIX: LONN

Q2 FY2025

Associate: Anne Ching

23 Jul 2025

​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​

• In H1 2025, Lonza delivered sales of CHF 3.6 billion with CER 1 growth of 19.0% and CORE EBITDA of CHF 1.1 billion, resulting in a margin of 29.6% (+0.4ppts versus H1 2024)
• CDMO 2 business delivered sales of CHF 3.1 billion with CER growth of 23.1% and CORE EBITDA of CHF 922 million, resulting in a margin of 30.2% (flat versus H1 2024)
• Sustained commercial momentum and high utilization levels in mammalian small-scale assets
• Capsules & Health Ingredients (CHI) business on track for expected recovery with flat CER sales versus H1 2024 and a CORE EBITDA margin improvement of +1.4ppts to 26.2%
• CDMO Outlook for FY 2025 upgraded to CER sales growth of 20-21% (previously “approaching 20%”) and a CORE EBITDA margin of 30-31% (previously “approaching 30%”)
• CHI Outlook for FY 2025 confirmed at low-to-mid single-digit percentages CER sales growth and an improved CORE EBITDA margin in the mid-twenties

Basel, Switzerland, 23 July 2025 – Lonza reported sales of CHF 3.6 billion in H1 2025, reflecting CER sales growth of 19.0% (17.0% AER 3 ). CHF 1.1 billion CORE EBITDA resulted in a robust margin of 29.6% (+0.4ppts versus H1 2024). Including the contribution from the recently acquired Vacaville (US) site, the CDMO business delivered CER sales growth of 23.1% and a CORE EBITDA margin of 30.2% (flat versus H1 2024), supported by good operational execution, disciplined cost management and maturing growth projects. The CHI business continued to improve as expected, with flat sales versus H1 2024 (0.0% CER) and an improved CORE EBITDA margin of 26.2% (+1.4ppts versus H1 2024).

CDMO sales in H1 benefited from an H1-weighted Vacaville performance and strong momentum in the Mammalian, Bioconjugates and Small Molecules Technology Platforms, with Bioscience returning to healthy growth. This positive momentum was partially offset by lower sales from Cell & Gene Technologies (CGT) and Microbial against a high comparison in H1 2024 and an H2-weighted delivery in 2025.

For Full-Year 2025, Lonza overall expects continued high utilization of its commercial assets with strong operational delivery and sustained commercial contracting across technologies of its CDMO business. There is continuing customer interest in the Vacaville large-scale mammalian drug substance facility, with multiple customer negotiations ongoing and further signings expected soon. Lonza also saw a high level of utilization in its mammalian small-scale assets in H1 2025 with good visibility for the remainder of the year, while closely monitoring the biotech funding environment and regulatory developments in the US, which may have an impact specifically on emerging technologies such as CGT. As previously communicated, Lonza continues to monitor the evolving geopolitical and macroeconomic landscape. Based on current knowledge, the business expects no material financial impact from US trade policies and remains confident it can support customers to mitigate the potential impact of tariffs.

Lonza’s new highly potent API 4 facility in Visp (CH) successfully commenced operations in Q1 2025 and ramp-up activities are progressing as planned. The large-scale mammalian drug substance facility, also located in Visp, successfully commenced GMP operations at the end of H1. At the Vacaville site, the first phase of capital expenditures to upgrade the site’s automation level and enhance its multi-purpose capabilities is well underway. Operations at Lonza’s new commercial-scale aseptic drug product facility in Stein (CH) are on track to begin in 2027, in line with the updated timeline.

On 1 April, Lonza successfully went live with its simplified and streamlined operating model to support its new One Lonza strategy. Centered around the Lonza Engine, the new operating model is designed to enhance customer experience, provide scalability for future growth and strengthen Lonza’s integrated multi-technology offering.

Outlook 2025

Lonza upgrades its Outlook for FY 2025 for the CDMO business to CER sales growth of 20-21% (previously “approaching 20%”) and a CORE EBITDA margin of 30-31% (previously “approaching 30%”). Excluding the business at Vacaville, which is expected to contribute around half a billion CHF in sales, Lonza expects low-teens percentage organic CER sales growth and margin improvement in its CDMO business. In line with this Outlook, Lonza expects sales in H2 2025 to be higher than in H1 with the CORE EBITDA margin at a similar level in H1 and H2.

Supported by good performance in H1 2025 and continuing market recovery, Lonza confirms the Outlook for FY 2025 for its CHI business to return to low-to-mid single-digit percentage CER sales growth, with an improved CORE EBITDA margin in the mid-twenties. For the mid-term, the CHI business is on track to return to its historical CER sales growth in the low-to-mid single-digit percentage and a CORE EBITDA margin above 30%.

For FY 2025, Lonza anticipates an FX 5 headwind of approximately -2.5 to -3.5% on sales and CORE EBITDA mainly from the weakening of the US Dollar, when assuming spot rates of early July 2025 will prevail for the remainder of the year. Margins will be only minimally impacted thanks to a robust natural hedge and Lonza’s financial hedging program.

Wolfgang Wienand, CEO, Lonza, commented: “The performance of One Lonza in the first half of 2025 is built on our position as a preferred CDMO partner for the biopharmaceutical industry and our ability to deliver at or above the commitments made to our customers. In a volatile macroeconomic environment, the resilience of the Lonza CDMO business is supported by the unique scale and reach of its global network, as well as the breadth and depth of its technologies.

“We continue to see sustained commercial demand across our CDMO business and drive our CapEx program forward. Our streamlined One Lonza operating model, which came into effect in April, will help us to deliver on our future growth ambitions and to strengthen our leading position in the market. It was inspiring to see how quickly the teams adapted to our new way of working while maintaining momentum in delivery.

“Finally, I would like to welcome Juan Andres, Eric Drapé and David Meline, all of whom were elected as new members of the Board of Directors at Lonza’s Annual General Meeting in May 2025. Their extensive experience and expertise in pharma manufacturing, quality and finance will be invaluable as we continue to drive performance and growth across our global network.”

Business Platform Overview

• Integrated Biologics reported strong CER 6 sales growth of 39.3% compared to H1 2024, supported by the Vacaville acquisition and sustained high demand for both large and small-scale assets. Good operational execution and maturing growth projects, together with the better than expected margin of the new Vacaville site, resulted in a CORE EBITDA margin of 36.0% (+0.5ppts versus H1 2024).
• Advanced Synthesis reported strong CER 6 sales growth of 18.3% compared to H1 2024, with both Small Molecules and Bioconjugates contributing. Supported by growth project ramp-up, operating leverage, and robust operational execution, CORE EBITDA margin reached 40.3% (+6.9ppts versus H1 2024).
• Specialized Modalities reported CER 6 sales at -9.2% and a CORE EBITDA margin of 17.3% (-6.1ppts versus H1 2024). Healthy growth in Bioscience was more than offset by CGT and Microbial, which compare against a high sales and CORE EBITDA base in H1 2024. Moreover, H1 2025 was impacted by pipeline variability, softer operational performance in CGT and a plant adaptation in Microbial. Lonza anticipates a better H2, with delivery weighted into Q4, in CGT and Microbial.
• Capsules & Health Ingredients progressed on its recovery path with flat CER 6 sales (0.0% CER versus H1 2024), confirming the projected trajectory for FY 2025. The capsules business has shown quarter-over-quarter CER sales growth since Q3 2024. The CORE EBITDA margin reached 26.2% (+1.4ppts versus H1 2024), supported by increased production volumes and the impact of productivity initiatives. The nutraceutical capsules business saw good order momentum in H1, while the pharma capsules business is on track to return to pre-Covid volumes in H2 2025. Preliminary affirmative determinations in recent US countervailing and antidumping filings are expected to restore competitive balance for nutraceutical and pharmaceutical capsules in the US. CHI’s large US footprint is expected to help customers navigate the evolving US tariff landscape. Lonza made good progress in H1 2025 with the internal preparations to carve out and exit the CHI business.

Group Financial Summary

CHF million	HYR 2025	YoY change (in %)	HYR 2024
Sales in AER	3,576	+17.0	3,057
Growth in CER in %	+19.0	+17.2ppts	+1.8
CORE EBITDA	1,059	+18.6	893
Margin in %	29.6	+0.4ppts	29.2
EBITDA	1,006	+16.7	862
Margin in %	28.1	-0.1ppts	28.2

For more details please refer to the Half-Year 2025 Presentation , Half-Year 2025 Report and Alternative Performance Measures (APM) 2025 Report .

• At Constant Exchange Rate (CER).
• CDMO: Lonza excluding Capsules & Health Ingredients (CHI).
• At Actual Exchange Rate (AER).
• Small molecule active pharmaceutical ingredients.
• Foreign exchange.
• Sales growth figures, expressed as a percentage (%) at Constant Exchange Rates (CER).

Source: ​​Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook​

COMPANY PROFILE

Lonza Group AG

SIX: LONN

Lonza is one of the world’s largest healthcare manufacturing organizations, helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our services and products span from supporting early-phase discovery to custom development and manufacturing of active pharmaceutical ingredients, as well as innovative dosage forms for the pharma and consumer health and nutrition industries. Our scale and resources mean that we can provide a single integrated solution to meet our customers’ complex needs. Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. Our global community, of around 18,000 employees, is comprised of high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. Our colleagues are the heart of our business and our global people strategy is designed to enable our colleagues to come, stay and grow at Lonza. While our business benefits from global supply chains, we have worked to maintain the agility to address marketplace needs on a local level.

About Us | Lonza |

BOARD OF DIRECTORS

NAME	DESIGNATION
Jean-Marc Huët	Chairman of the Board of Directors of Lonza Group Ltd (since May 2024), Independent member of the Board of Directors of Lonza Group Ltd (since May 2024)
Jürgen Steinemann	Vice-Chairman of the Board of Directors of Lonza Group Ltd (since August 2024); Independent member of the Board of Directors of Lonza Group Ltd (since April 2014)
Christoph Mäder	Lead Independent Director of the Board of Directors of Lonza Group Ltd (since November 2019); Independent member of the Board of Directors of Lonza Group Ltd (since April 2016)
Roger Nitsch	Independent member of the Board of Directors of Lonza Group Ltd (since May 2022)
Marion Helmes	Independent member of the Board of Directors of Lonza Group Ltd (since May 2022)
Angelica Kohlmann	Independent member of the Board of Directors of Lonza Group Ltd (since May 2018)
Barbara Richmond	Independent member of the Board of Directors of Lonza Group Ltd (since April 2014)
Olivier Verscheure	Independent member of the Board of Directors of Lonza Group Ltd (since May 2018)

Board of Directors | Lonza

EXECUTIVE TEAM

NAME	DESIGNATION
Wolfgang Wienand	Chief Executive Officer (CEO) and Member of the Executive Committee (since July 2024)
Philippe Deecke	Chief Financial Officer (CFO) and Member of the Executive Committee (since December 2021)
Maria Soler Nunez	Head, Group Operations and Member of the Executive Committee (since August 2022)
Christian Seufert	President, Capsules & Health Ingredients Division (since July 2022) and Member of the Executive Committee (since July 2022)
Gordon Bates	President, Small Molecules Division (since January 2021) and Member of the Executive Committee (since April 2021)
Jean-Christophe Hyvert	President, Biologics (since January 2021) and Member of the Executive Committee (since April 2021)
Daniel Palmacci	President, Cell & Gene (since November 2022) and Member of the Executive Committee (since November 2022)

Leadership | Lonza

CORPORATE SOCIAL RESPONSIBILITY

17 Apr 2024

Lonza Signs Multiple Renewable Energy Certificate Agreements in the United States

• Lonza signs three Renewable Energy Certificate (REC) purchase agreements in the United States (US), supporting the commissioning of additional renewable energy projects
• The RECs will enable all current Lonza facilities in the US to achieve 100% renewable electricity
• The agreements reflect Lonza’s continuing commitment to decrease its carbon footprint

Basel, Switzerland, 17 April 2024 - Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has entered into agreements to purchase Renewable Energy Certificates (RECs) from Clearway Energy Group’s (Clearway) recently constructed Texas Solar Nova 1 and 2 projects in Kent County, TX (US). Commencing in January 2026, the agreements will provide Lonza with a total of 235,000 RECs, effectively decarbonizing an equal number of megawatt-hours (MWh) of consumed electricity per year.

This is Lonza’s first REC procurement at scale in the US, and will enable the company to offset 100% of annual electricity consumption at its current US facilities. The REC agreements, along with two other major Power Purchase Agreements (PPAs) previously signed in Europe and China, support Lonza’s ambition to purchase all electricity from renewable sources where available by 2025. Collectively, these agreements mark a significant step forward Lonza’s near-term emission reduction targets which were recently approved by the Science Based Targets initiative (SBTi).

Maria Soler Nunez, Group Head of Operations, Lonza, commented: “We are committed to reducing our environmental footprint, while supporting the commissioning of additional renewable energy projects, thereby directly contributing to a greener and more sustainable future. These long-term REC agreements align with our commitments and targets, representing a significant milestone towards reaching carbon neutrality by 2050.”

“Lonza’s commitment to achieving its sustainability goals is helping power the clean energy transition,” said Valerie Wooley, Senior Vice President of Origination at Clearway. “We’re proud that our solar project in Kent County will help Lonza achieve its goals through a long-term REC agreement.”

The Texas Solar Nova projects utilize cutting-edge bifacial solar collector technology, ensuring efficient conversion and maximum yield of renewable energy. Additionally, the RECs generated from Clearway's solar farms will be listed with the Center for Resource Solutions (CRS), ensuring compliance with all requirements for certification pursuant to the US Green-e Renewable Energy Standard.

A REC is a legal and market instrument issued per megawatt-hour of power, verifying claims of renewable electricity use.

Source: Renewable Electricity in the US (lonza.com)

16 Jan 2024

Five Global Healthcare Leaders Secure Industry-first, Multi-party Agreement to Access Renewable Power in China

• AstraZeneca, Lonza, Novartis, Novo Nordisk and Roche have signed an agreement in China with leading green technology company Envision Energy to unlock access to renewable power, resulting in potential annual carbon dioxide equivalent savings of approximately 120,000 tonnes.

Davos, Switzerland – To accelerate the transition to net zero health systems, five global healthcare companies, including four members of the Sustainable Markets Initiative Health Systems Task Force , have signed an industry-first, multi-party renewable power agreement in China. This is the first time that companies from across the global healthcare sector – AstraZeneca, Lonza, Novartis, Novo Nordisk and Roche – have come together to decarbonise their operations in China.

The three-year renewable energy supply agreement, announced at the World Economic Forum in Davos, Switzerland, supports China’s journey towards carbon neutrality and will unlock around 200 gigawatthours (GWh) of renewable electricity annually from 2024 onwards in Jiangsu, Guangdong, Shanghai and Beijing. This will result in annual emissions savings of approximately 120,000 tonnes of carbon dioxide equivalent (CO2e), comparable to taking 25,000 cars off the road. 1

The completion of this agreement follows the announcement of advanced discussions ahead of COP28 and opens up additional opportunities for companies in the healthcare supply chain to join and decarbonise their operations. The electricity will be supplied by Envision Energy, one of China’s largest renewable energy companies.

The healthcare sector contributes approximately 5% of global emissions 2 . Over half of the sector’s emissions are created in manufacturing supply chains, and energy consumed in these supply chains accounts for around 25% of total healthcare emissions. China is a key market for pharmaceuticals manufacturing, making collaboration with this market critical to reduce carbon emissions at scale.

The four participating members from the Sustainable Markets Initiative Health Systems Task Force are: AstraZeneca, Novartis, Novo Nordisk, and Roche.

Envision Energy is a member of the China Council Health Working Group which was launched by the Sustainable Markets Initiative‘s China Council in November 2023. This Working Group aims to accelerate the delivery of sustainable healthcare in China, with broader global impact and is comprised of 16 Chinese companies from the health, energy and digital sectors, alongside members of the Health Systems Task Force.

The Sustainable Markets Initiative’s Health Systems Task Force is committed to continued delivery across its initiatives in 2024, including the development of frameworks to measure the environmental impact of medicines and delivery of patient care.

1 https://www.epa.gov/greenvehicles/greenhouse-gas-emissions-typical-passenger-vehicle

2 https://a.storyblok.com/f/109506/x/96fc198cb8/smi-hstf-executive-summary.pdf

Source: Renewable Electricity in China (lonza.com)

COMPETITORS

Novo Nordisk (Nasdaq: NOVO B)

We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.

Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 69,000 people in 80 offices around the world, and market our products in 170 countries.

Who we are (novonordisk.com)

Thermo Fisher Scientific (Nasdaq: TMO)

Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.

About (thermofisher.com)

Amgen (Nasdaq: AMGN)

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.

Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and we are also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

About | Amgen

CSL (ASX: CSL)

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.

We Are CSL | CSL

Gilead Sciences (Nasdaq: GILD)

For more than 35 years, we've been tackling some of the world’s greatest public health challenges, revolutionizing HIV treatment and prevention and delivering a cure for hepatitis C. Now, we're working to discover and advance therapies that offer new hope to patients impacted by diseases across our therapeutic areas of Virology, Oncology and Inflammation. At Gilead, we strive to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we deliver innovative therapies that offer new hope to those impacted by disease. We invest in world-class science and are pursuing innovation across our therapeutic areas of virology, oncology and inflammation.

Gilead Sciences: Company

Vertex Pharmaceuticals (Nasdaq: VRTX)

We strike at the core of serious diseases to change people’s lives. Bringing together the brightest minds, investing in science and taking smart risks, we go all in. For the lives we have changed and for those who are still waiting, we will never stop fighting until we discover cures. We have research and development sites and commercial offices around the world, all dedicated to bringing the next transformative treatments to people with serious diseases. Our headquarters are in Boston and London.

Vertex Pharmaceuticals | Our Company (vrtx.com)

Regeneron Pharmaceuticals (Nasdaq: REGN)

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

About Regeneron Pharmaceuticals: Innovative Biotechnology

Daiichi Sankyo (TYO: 4568)

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world. With more than 120 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 17,000 + employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

About Us - Daiichi Sankyo

Jiangsu Hengrui Pharmaceuticals (SSE: 600276)

Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The company's products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hrssd.com.cn)

Chugai Pharmaceutical Co., Ltd (TYO: 4519)

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group.

About Chugai | CHUGAI PHARMACEUTICAL CO., LTD. (chugai-pharm.co.jp)

Biogen (Nasdaq: BIIB)

Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world. Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.

Company | Biogen

Lonza (SIX: LONN)

Lonza is one of the world’s largest healthcare manufacturing organizations, helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our services and products span from supporting early-phase discovery to custom development and manufacturing of active pharmaceutical ingredients, as well as innovative dosage forms for the pharma and consumer health and nutrition industries. Our scale and resources mean that we can provide a single integrated solution to meet our customers’ complex needs.

About Us | Lonza |

Samsung Biologics (KRX: 207940)

Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products. Our facilities are all CGMP compliant with bioreactors ranging from small to large scales to serve varying client needs.

To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demands, Samsung Biologics launched Plant 4, which will further advance the company’s standing as the world’s largest manufacturing facility at a single site—holding a 604 kL total capacity—and announced plans to construct Plant 5, which will be operational in 2025.

As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

Our DNA | Company | About Us | SAMSUNG BIOLOGICS

Agilent Technologies, Inc (S&P 500)

Agilent supports scientists in 110 countries in cutting-edge life science research; patient diagnostics; and testing required to ensure the safety of water, food and pharmaceuticals Our advanced instruments, software, consumables, and services enable our customers to produce the most accurate and reliable results as well as optimal scientific, economic, and operational outcomes.

We play a role in advancing important research and testing, with our scientists creating some of the world's most leading-edge technology and our field engineers working side by side with customers to help them maximize productivity. We bring these solutions to a variety of markets, from pharma and diagnostics to applied materials and chemicals. Together with our customers, we’re bringing great science to life.

About Agilent - Agilent

Seagen (Nasdaq: SGEN)

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.

As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology. We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.

Our Mission, Vision, and Values – Seagen

Illumina, Inc (Nasdaq: ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Illumina | Sequencing and array solutions to fuel genomic discoveries

WuXi AppTec (SSE: 603259)

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

About Us | WuXi AppTec

Sun Pharmaceutical Industries Limited (BSE: 524715)

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of US$ 5.4 billion. Supported by 43 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Our broad portfolio of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.

Every year, we sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.

About Us - Sun Pharmaceutical Industries Ltd.

BeiGene (Nasdaq: BGNE)

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Our Mission, Vision & Values | BeiGene

BioNTech SE (Nasdaq: BNTX)

BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large-scale products like our COVID-19 vaccine. We are also continuously evaluating ways to democratize the access to healthcare in the long-term. While BioNTech, together with its partner Pfizer, has led the global COVID-19 vaccine effort and made great strides in individualized cancer treatments, its story is just beginning. BioNTech’s portfolio contains more than 25 product candidates in clinical trials.

In pursuit of changing the treatment paradigm with individualized cancer therapies, our pipeline encompasses oncology product candidates including individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immunomodulators, targeted cancer antibodies and small molecules.

BioNTech | Our mission: basic research in mRNA technology and improving health

Genmab (Nasdaq Copenhagen: GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

About | Genmab

Alnylam Pharmaceuticals (Nasdaq: ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam® Pharmaceuticals

WuXi Biologics (SEHK: 2269)

WuXi Discovery Services supports clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, we work collaboratively to rapidly advance programs from target through to preclinical selection and beyond. This integration of capabilities allows a collaborative environment, enabling enhanced efficiency and productivity. We strive to continually develop and enhance our scientific capabilities and technology to maintain its industry leading position. We aim to provide outstanding services to our existing partners and to the broader discovery community.

About WuXi Biology - WuXi Biology

Argenx (Nasdaq: AGRX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx | Homepage - Reaching Patients Through Immunology Innovation

THE INDUSTRY

Source: LONN.SW Interactive Stock Chart | Lonza Group AG Stock - Yahoo Finance

The Global Biotechnology Industry Outlook - 2024

The global BioTech Industry was above average in terms of performance last year. It was full of innovations, new technologies entered the market, new approvals such as first CRISPR gene therapy, Casgevy created history. Innovations in healthcare technology kept the morales of the stakeholders high amid market volatility. The commitment of companies launching novel cell and gene therapies to revolutionize patient lives can be realized through effective preparation of the market, their products, and internal go-to-market strategies.

2024 alone is projected to see the launch of up to 21 cell therapies and 31 gene therapies. Personalized mRNA vaccines in cancer (such as melanoma, pancreas, and others) will be an emerging therapy this year.

MarketsandMarkets has identified more than 10 global trends in the entire BioTech value chain and the report Global BioTech Industry Outlook 2024 analyses the events of 2023 while exploring new opportunities in 2024.

Performance of the last year i.e. 2023

• The global biotech industry grew from USD 366.7 bn in 2022 to USD 412.2 bn in 2023, at a CAGR of 12.3%.
• Genomics was one of the hottest segments in this period, as it grew from USD 18.9 bn in 2022 to USD 19.6 bn in 2023, with the DNA sequencing segment leading the market followed by PCR techniques.
• Allogeneic cell therapy, microbiome marvels, and CRISPR- Cas9 technology were hot in many markets, especially the US. In 2023, medicine based on gene editing was approved for the first time.
• Biologics safety testing attracted stakeholders as it grew from USD 3.7 bn in 2022 to USD 4.0 bn in 2023.
• M&A in biotech was slightly low compared to previous years but still better than Medtech segments, as major players acquired companies to strengthen their drug pipelines. It started on a good note but dipped beyond Q3’23, attributed to the war in Israel, rising crude oil prices, supply chain disruptions, and market volatility, among other reasons.
• FDA and regulatory bodies in Europe, China, Australia, India, and others are taking a special interest in gene-editing therapies.
• According to HSBC data, the first half of 2023 saw investors injecting USD 2 billion into 81 seed and Series A deals for biotech companies, marking a slower pace compared to the preceding three years. The overall venture investment in the sector amounted to USD 10.6 billion across 320 deals, figures that also fall below recent levels.
• Overall, biotech attracted favorable sentiments, as companies thrive in north America and Europe. China was a confusing market, as VBP brought down the profit margins of many drug manufacturers, with further losses expected in Q4 2023 (new tenders were floated in Oct’23 and results expected in Jan’24) once the financial results are out in early 2024.

Biotechnology: Revolutionizing Healthcare from the Inside Out

Biotechnology is leading the way in the paradigm shift in healthcare by fusing cutting-edge technology with biological processes to produce game-changing solutions. This dynamic field—often shortened to "healthcare biotech"—is drastically changing the medical environment by providing never-before-seen possibilities for prevention, diagnosis, and treatment.

One of the most significant impacts of biotech in medical field lies in its ability to target diseases at their very core. Through the utilization of cells, genes, and biomolecules, scientists are creating novel treatments that target the underlying causes of diseases rather than just their symptoms. Just a few instances of the revolutionary potential of healthcare biotech include personalized cell therapies that regenerate damaged tissues or genetically engineered viruses that target cancer cells specifically.

Beyond therapy, biotech is transforming diagnostics in the medical field. Advanced genetic and molecular analysis has revealed biomarkers that enable earlier and more precise disease detection, prompt intervention, and better patient outcomes. Imagine personalized cancer screenings based on unique genetic profiles, or non-invasive blood tests that identify early indicators of Alzheimer's disease. These developments provide vital information for better informed healthcare decisions, empowering physicians and patients alike.

Moreover, personalized medicine is being made possible by the use of biotechnology in healthcare. Medical professionals are able to customize treatments and interventions to the individual needs of each patient by knowing that each patient has a unique genetic makeup and biological response. This biotech-driven strategy has great potential to reduce side effects and increase treatment efficacy, which will ultimately result in a future of truly effective and personalized healthcare.

However, navigating the exciting world of biotech in the medical field also requires careful consideration of ethical and regulatory challenges. Maintaining patient safety, equitable access, and responsible development are still of utmost importance. Following these guidelines will be essential as we delve deeper into this revolutionary field in order to fully utilize healthcare biotech for everyone's benefit.

In summary, biotechnology in healthcare is more than just a catchphrase; it's a major force behind advancement and innovation in the industry. The future of healthcare is clearly entwined with biotech advances, ranging from personalized medicine and targeted therapies to advanced diagnostics and regenerative solutions. We can give future generations a healthier future by wisely navigating the difficulties and utilizing this field's enormous potential.

Navigating the Maze: Major Players in the Global Biotechnology Industry

The global biotechnology sector, teeming with biotechnology companies (often shortened to biotech companies), is a dynamic and diverse landscape fueled by innovation and discovery. These businesses, which range from agile startups to massive pharmaceutical companies, are advancing science and medicine and influencing the direction of healthcare.

Among the major players in this biotechnology sector are established biotech companies like Amgen, Gilead Sciences, and Biogen. These seasoned professionals in the field have a vast array of approved medications and treatments, especially in the fields of immunology, oncology, and rare diseases. Their R&D pipelines are full of promising candidates, so there will always be a fresh supply of cutting-edge treatments available to patients around the globe.

Beyond established names, the biotechnology sector is buzzing with smaller, agile biotech companies known for their niche expertise and disruptive potential. These businesses frequently concentrate on particular disease categories or cutting-edge medical innovations like gene editing or personalized care. Examples are CRISPR Therapeutics, at the forefront of gene editing applications, and Moderna, a pioneer in mRNA technology. These versatile players add fuel to the innovation engine, commonly work alongside larger biotech companies to bring breakthroughs to reality.

The biotechnology sector is not limited to any one area when it comes to geography. With well-known titans like AbbVie and Amgen, North America is home to strongholds like Roche and Novo Nordisk, but Europe is truly remarkable. With businesses like BeiGene and WuXi AppTec making major advancements in R&D and drug development, Asia, and China in particular, is quickly becoming a central role. Progress in the biotechnology sector is accelerated by the global environment, which encourages healthy competition and collaboration.

Navigating the complexities of the biotechnology sector is not without its difficulties, though. Obstacles to entry and expansion can include fierce competition, intricate regulatory requirements, and the high cost of research and development, especially for smaller bio technology companies. Furthermore, cautious navigating of the ethical issues surrounding gene editing and personalized medicine is necessary to guarantee responsible development and fair access.

In spite of these obstacles, the biotechnology sector has an unquestionably bright future. Bio technology companies have the potential to completely transform healthcare by providing solutions for unmet medical needs and enhancing the lives of patients all over the world. This can be achieved through sustained technological advancements, growing collaboration, and increased investment. To fully realize the enormous potential of this rapidly expanding industry and create a healthier future for all, it will be imperative that we remain informed about the major players, new trends, and moral issues as we go forward.

Peering into the Future: Emerging Trends Driving Growth in the Global Biotech Industry

Rising trends that have the potential to completely transform healthcare are driving a recent surge in growth in the global biotechnology industry, which is teeming with innovation and discovery. These biotech trends are influencing how the medical field and patient care will develop in the future, from using artificial intelligence to its full potential to discovering the mysteries of the microbiome.

The incorporation of artificial intelligence (AI) is one of the key biotechnology trends propelling growth. Artificial intelligence (AI) algorithms are revolutionizing drug discovery by sifting through enormous datasets to find possible drug targets and quicken the development process. Envision AI-driven systems sorting through millions of compounds to determine their potential for therapeutic use, greatly cutting down on the time and expense required to introduce new medications to the market.

AI is influencing other important facets of the biotechnology industry growth in addition to drug discovery. Imagine superhuman accuracy in medical image analysis by AI-powered diagnostics, resulting in earlier and more accurate diagnosis. Alternatively, think about robotic surgery with AI assistance, which offers patients minimal invasiveness and enhanced precision. These AI-powered innovations aren't just sci-fi ideas; they're the biotechnology trends that are actively driving the sector forward.

The study of the microbiome is another emerging trend in the biotechnology sector. Our bodies are home to a complex ecosystem of bacteria that has enormous potential for diagnosing and treating a wide range of illnesses. Scientists are investigating the potential of modifying the microbiome to treat allergies, inflammatory bowel disease, and even specific types of cancer. Imagine customized probiotic regimens based on each person's distinct microbiome, opening the door for profoundly impactful biotechnology-driven solutions.

Furthermore, personalized medicine is a major biotechnology trend. Through the analysis of biomarkers and genetic composition, scientists are able to customise treatments for individual patients. The trend toward personalization has great potential to increase treatment effectiveness and reduce adverse effects. Imagine treatments for cancer that precisely target specific mutations or immune-oncology procedures that use the patient's own immune system to combat the illness. Future biotech trends point to a time when personalized healthcare will replace the current one-size-fits-all approach.

However, navigating the exciting world of emerging biotechnology trends requires careful consideration. Ensuring responsible development, equitable access, and patient safety remains paramount. As we venture deeper into this transformative field, upholding these principles will be crucial to harnessing the full potential of biotechnology for the benefit of all.

About 80% of the Forbes Global 2000 B2B companies rely on MarketsandMarkets to identify growth opportunities in emerging technologies and use cases that will have a positive revenue impact.

In conclusion, new trends like microbiome research, AI integration, and personalized medicine are driving the biotechnology industry growth and innovation going forward. Through responsible navigation of the obstacles and harnessing of the enormous potential of these developments, the industry can build a more promising future in which biotechnology-driven solutions enhance patient outcomes globally.

Source: The Global Biotechnology Industry Outlook - 2024 (marketsandmarkets.com)

Biotechnology Market Size | Share and Trends 2024 to 2034

The global biotechnology market size was USD 1.38 trillion in 2023, calculated at USD 1.55 trillion in 2024 and is expected to reach around USD 4.61 trillion by 2034, expanding at a CAGR of 11.5% from 2024 to 2034.

Biotechnology Market Size and Forecast 2024 to 2034

The global biotechnology market size accounted for USD 1.55 trillion in 2024 and is expected to reach around USD 4.61 trillion by 2034, expanding at a CAGR of 11.5% from 2024 to 2034. The North America biotechnology market size reached USD 521.02 billion in 2023.

Biotechnology Market

Key Takeaway

• North America accounted for a revenue share of 37.79% in 2023.
• Asia Pacific has generated a revenue share of 23.99% in 2023.
• By application, the bio-pharmacy segment has captured 41.73% revenue share in 2023.
• The bio-industries application segment held a 24.33% revenue share in 2023.
• By technology, the tissue engineering and regeneration segment has garnered a 19.26% revenue share in 2023.

U.S. Biotechnology Market Size and Growth 2024 to 2034

The U.S. biotechnology market size was estimated at USD 246.18 billion in 2023 and is predicted to be worth around USD 830.31 billion by 2034, at a CAGR of 11.6% from 2024 to 2034.

Based on the region, the North American region dominated the global biotechnology market with revenue share in 2023. Several factors, including the existence of important competitors, strong R&D initiatives, and high healthcare expenses, have contributed to the North America region market growth. Furthermore, a growing number of businesses operating in the region are gaining drug approvals, which is fueling market expansion.

The Asia-Pacific is estimated to hit a growth rate of over 12.4% during the forecast period. The improvement of healthcare infrastructure, clinical trial services, and supportive government regulations are all contributing to the Asia-Pacific biotechnology market growth. Moreover, the international market players are partnering actively with local companies in order to accelerate the biotechnology market’s growth.

Growth Factors

Biotechnology is a branch of science that develops or creates products by utilizing biological systems, living creatures, or elements out of them. Biotechnology now encompasses a wide range of fields such as biochemistry, genetics, and molecular biology. Every year, new technologies and products are developed in fields such as medical, agriculture, and industrial biotechnology.

Due to the rise of the biotechnology sector in developing nations such as China, Japan, and India, the market is being driven by favorable government initiatives. The government activities are aimed at streamlining the medication regulatory pathway, standardizing clinical studies, enhancing reimbursement policies, and expediting the product approval process, all of which will provide the industry with lucrative growth potential.

Furthermore, agricultural input firms are concentrating their efforts on upgrading existing technologies, such as the development of new stacked features in crops and new germplasm through breeding innovations and gene sequencing. The key market players are concentrating their efforts on bringing agricultural innovations to market in order to boost production through long-term solutions.

The rising incidences of target diseases and genetic disorders, as well as continuous technological advancements in Polymerase Chain Reaction (PCR) technologies, the development of miniaturized portable instruments, and the incorporation of robotics, as well as increased investments, funds, and grants for research activities, are driving the growth of the biotechnology market during the forecast period.

The use of genomic analytic techniques such as microbial identification and detection of genetic changes in the diagnosis of major infectious diseases like HIV, malaria, and TB and genetic abnormalities has developed rapidly over the last decade. The expansion in the global prevalence of target diseases, together with the demonstrated usefulness of Polymerase Chain Reaction (PCR) analysis in the diagnosis and estimation of disease-causing bacteria, will drive up the use of clinical diagnostic tests and will ultimately boost the growth of biotechnology market.

The rising frequency of infectious and chronic diseases as well as increased research and development investments to develop breakthrough genomic techniques such as cell based assay and polymerase chain reaction (PCR), are likely to drive significant development in emerging countries. In developing regions, the biotechnology market growth will be aided by the rise in healthcare spending, the expansion of healthcare infrastructure, and lower procedural costs of disease diagnosis techniques.

The expansion of healthcare infrastructure in emerging countries is accompanied by rapid growth of healthcare facilities and modernization. This aspect is contributing to diagnostic laboratories’ increasing demand for clinical diagnostic procedures, which is leading in higher sales and revenue growth of biotechnologies in the market.

Biotechnology is becoming more important since large amounts of data generated by techniques such as nucleic acid and protein acid sequencing require data interpretation and management for medical and future research objectives. Consequently, the biotechnology market is likely to be driven by increased demand over the forecast period.

Market Scope

Report Coverage	Details
Growth Rate from 2024 to 2034	CAGR of 2034%
Market Size in 2023	USD 1.38 Trillion
Market Size in 2024	USD 1.55 Trillion
Market Size by 2034	USD 4.25 Trillion
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2023
Forecast Period	2024 to 2034
Segments Covered	Application, Technology, Region
Regions Covered	Asia Pacific, North America, Europe, Latin America, Middle East and Africa

Application Insights

Based on the application, the bio-pharmacy dominates the biotechnology market during the forecast period. The increasing prevalence of diseases is mostly responsible for the growth of the segment. Thus, the rising demand for medicines and drugs is driving the growth of the bio-pharmacy segment in the biotechnology market.

On the other hand, bio-informatics is expected to grow at a rapid pace of 12.6% during the forecast period. The rising demand for nucleic acid and protein sequencing, rising initiatives from private and government organizations, propelling the growth of proteomics and genomics , and rising research on molecular biology and drug discovery are all growth factors for the bio-informatics segment. The bio-informatics segment is predicted to increase rapidly during the forecast period as a result of the aforementioned factors.

Technology Insights

The tissue engineering and regeneration segment held the dominating share of the market in 2023. Tissue engineering and regeneration technologies are finding applications across a broad spectrum of healthcare domains, including orthopedics, cardiology, dermatology, and neurology. The versatility of these approaches in addressing diverse medical needs further strengthens their dominance in the biotechnology market. Regulatory agencies worldwide are increasingly recognizing the potential of tissue engineering and regeneration technologies and providing support for their development and commercialization. Clinical validation through successful trials and regulatory approvals has bolstered confidence in these approaches, paving the way for their widespread adoption and market dominance.

The chromatography segment is observed to grow at the fastest pace during the forecast period. Chromatography techniques offer unparalleled analytical precision, allowing biotechnologists to separate and analyze complex mixtures of biomolecules with high resolution and accuracy. This precision is crucial for various applications in biotechnology, including drug discovery, proteomics, genomics, and quality control. Chromatography techniques, particularly affinity chromatography, ion exchange chromatography, and size exclusion chromatography, are essential for protein purification in biotechnology research and production. These techniques enable the isolation and purification of target proteins from complex biological matrices, facilitating downstream applications in biopharmaceuticals, diagnostics, and research.

Source: Biotechnology Market Size to Worth Around USD 4.25 Trillion by 2033 (precedenceresearch.com)

ACQ_REF: CS/18146/20250812/99675/CHE/31/4

ACQ_AUTHOR: Associate/Anne Ching